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Abstract: Ovarian hyperstimulation 
syndrome caused by assisted 
reproductive technology can lead to 
pulmonary embolism, a rare but serious 
side effect. 
 
Case Presentation 
 
A gravid 21 year old G1P0 was admitted 
to the local emergency room 2 days s/p 
in vitro fertilization (IVF) embryo transfer 
(cycle #2) with shortness of breath.  She 
also had abdominal distention, bloating 
and nausea at that time.  Her initial lab 
work-up showed hemoconcentration 
and elevated D-dimer (Table 1).  She 
had a chest CT scan in the ER that 
revealed a right pulmonary embolus 
(PE) and small right pleural effusion.  
The patient was started on an 
unfractionated heparin drip and was 
transferred to our hospital for further 
care.  Upon admission to our institution, 
the patient was tachycardic but 
appeared in no acute distress.  The 
patient was started initially on low 
molecular weight (LMW) heparin at 
1mg/kg (100mg) BID for anticoagulation 
and her unfractionated heparin drip was 
discontinued. 
The patient’s history was complicated by 
primary infertility due to a combination of 
oligoovulation and male factor. Her 
medical history is significant for 
polycystic ovary syndrome and obesity.  
Her situation was also complicated by 
male factor infertility.  She is a lifelong 
non-smoker.  She had used oral 
contraceptive pills for one year prior to 
attempting to conceive.   
 
The patient had a baseline ultrasound 
that showed polycystic ovaries (Table 
2). She was started on the following 
protocol for ovulation induction: 
leuprolide 1 mg on, FSH 150 units, and 
metformin.  The plan for insemination 
was intracytoplasmic sperm injection 
(ICSI).  Her first cycle resulted in four 
oocytes retrieved and inseminated by 
ICSI; one embryo was transferred but 
did not result in pregnancy.  For her 
second cycle, 16 oocytes were retrieved 
and six inseminated by ICSI.  One 
embryo was transferred on cycle 2.  
 
Two days after embryo transfer, the 
patient had nausea and vomiting and 
was given promethazine.  The following 
day she was admitted to the local 
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hospital with shortness of breath and 
was diagnosed by CT scan with the PE.  
She was treated with LMW heparin at 
100 mg BID, which was continued as an 
outpatient.  Her lab values showed 
hemoconcentration (Table 1), and this 
combined with her clinical presentation 
gave her the diagnosis of severe 
ovarian hyperstimulation syndrome 
(OHSS).   
 
On day 15 post-conception, the patient 
had a positive pregnancy test with 
quantitative beta-hCG 48 (table 1).  
Ultrasound done two weeks later 
showed enlarged ovaries bilaterally, 
consistent with OHSS (table 2).   
 
Table 1 (laboratory values, 
*abnormal) 
Initial presentation to 
ER:  
 
Creatinine 1.3 
Hemoglobin 17.8* 
Hematocrit 51%* 
D-dimer 811* 
Quantitative hCG 13 
Positive pregnancy 
test: 
 
Quantitative hCG 48 
Progesterone 229 
Estradiol >200 
Hypercoaguability 
workup: 
 
Anticardiolipin 
antibody 
IgM 10.1 mpl, 
IgG 4.8 gpl 
(normal) 
Beta-2-glycoprotein IgM 4.1 smu, 
IgG 2.3 sgu 
(normal) 
Dilute viper venom 
assay 
Within normal 
limits (40 
seconds 
corrected) 
Factor V Leiden No detected 
mutations 
 
The patient’s pregnancy progressed well 
until she was diagnosed with mild 
preeclampsia at 35 weeks gestation.  
She presented with blood pressures in 
the 140s/90s and a 24 hour urine 
protein of 395 mg.  There was no 
evidence of renal insufficiency, 
thrombocytopenia or elevated liver 
transaminases.  Patient was transitioned 
to unfractionated heparin (dosed every 8 
hours) at the time of admission and 
LMW heparin was discontinued.  The 
patient had a rapid response to heparin, 
and her dosing was adjusted daily 
(Table 3).  A thrombophilia work-up was 
done during her admission and found to 
be negative (Table 1).  The patient 
underwent labor induction at 37 0/7 
weeks and was delivered by primary low 
transverse cesarean delivery at 37 1/7 
weeks gestation for failure to descend.  
Her heparin was stopped 12 hours prior 
to delivery. 
 
Table 2 (ultrasound results) 
Pre-assisted reproductive technology  
 Size: 
(L x W 
x H) 
Volume: Antral 
Follicles: 
Left 
Ovary 
42 x 
29 x 
26 mm 
17 cc 28 
Right 
Ovary 
43 x 
33 x 
27 mm 
20 cc 22  
Ultrasound post-ICSI and positive 
pregnancy test  
 Size (L x W x H): 
Left Ovary 128 x 79 x 84 mm 
(enlarged)* 
Right Ovary 135 x 96 x 77 mm 
(enlarged)* 
 Multiple corpus 
luteum cysts 
Assigned 
gestational age: 
5 5/7 weeks 
gestation 
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Table 3 (Anticoagulation response) 
Heparin Dose: PTT* following 24 
hours Heparin 
dose: 
Initial dose 12,000 
units TID 
105 
Decreased to 6,000 
units TID 
48 
Increased to 7,000 
units TID 
59 
Continued 7,000 
units TID 
69-80 
*PTT – partial thromboplastin time (Goal 
60-80) 
 
Postpartum she received 24 hours of 
magnesium sulfate therapy for seizure 
prophylaxis and was started on 
therapeutic doses of LMW heparin 12 
hours postpartum.  She had an episode 
of heavy bleeding from her incision on 
postoperative day 3.  Superficial 
exploration showed intact fascia and 
generalized bleeding from 
subcutaneous vessels that were 
cauterized and sutured.  Her 
anticoagulation was discontinued.  She 
was transfused 3 units of packed red 
blood cells and was discharged on 
postoperative day 6 from her cesarean 
delivery without anticoagulation therapy.  
The decision was made to not 
anticoagulate her on discharge because 
she had received 6 months of therapy 
following her PE, and the inciting factor 
of OHSS had since resolved.  She will 
receive the Mirena IUD for contraception 
at her 8 week postpartum visit. 
  
Discussion 
 
Approximately 20.5 million people 
worldwide are currently seeking medical 
care for infertility, including assisted 
reproductive technology (ART).  It is 
estimated that the prevalence of short-
term complications of ART is 2%, with 
ovarian hyperstimulation syndrome 
(OHSS) accounting for half of all 
complications.  OHSS can be a 
complication of any medication used for 
ovulation induction and is most common 
with the use of gonadotropins or 
clomiphene citrate.1 The majority of 
studies estimate that clinically relevant 
OHSS occurs in up to 10% of cycles 
with 2% of these cases being life-
threatening or severe.   
 
OHSS is mostly a direct consequence of 
excessive follicular response to 
stimulation of the ovaries by pregnancy-
induced endogenous hCG elevations or 
exogenous hCG administration.2 The 
underlying mechanism of OHSS is not 
entirely known.  However, this excessive 
follicular stimulation and the release of 
vasoactive substances have been 
shown to lead to third-space fluid 
accumulation and hemoconcentration 
leading to hemodynamic and respiratory 
alterations.  These alterations can lead 
to thromboembolic phenomena.3 The 
main mechanism of third-space fluid 
accumulation is thought to be due to 
increased vascular permeability.  
However, several ovarian factors such 
as the rennin-angiotensin system, 
cytokines, or vascular endothelial 
growth factor (VEGF) have been 
thought to play a role.4 It is important to 
diagnose polycystic ovaries (PCO) prior 
to ovarian stimulation because these 
patients are more likely to develop 
OHSS.  The risk of OHSS in PCO 
patients can be minimized by using a 
low-dose gonadotropin regimen as 
opposed to high-dose regimen.2  
 
Recently, VEGF has been found to play 
an important role in the pathophysiology 
of OHSS because it leads to increased 
vascular permeability in the ovary.  
There is increasing evidence that VEGF 
Ovarian hyperstimulation syndrome and development of pulmonary embolism in pregnancy 3
Proceedings in Obstetrics and Gynecology, 2010 Apr;1(1):11 
Case Report 
concentrations increase the risk, 
incidence and course of OHSS.5  
Dopamine binding to the VEGF receptor 
has shown to cause an inhibition of 
VEGF signaling, therefore leading to 
decreased vascular permeability.  The 
use of cabergoline, a dopamine agonist, 
has been found to prevent OHSS when 
used prophylactically during ART 
without having an adverse effect on the 
outcome of ART.  However, this data 
has not been extensively studied.1 
 
The increased risk of thrombosis found 
in OHSS is related to several factors.  A 
strongly recognized mechanism is 
hemoconcentration, leading to elevated 
blood viscosity and vascular stasis due 
to decreased flow of the blood stream.  
Venous thromboembolism is thought to 
occur more commonly than arterial 
thrombosis (75 and 25%, respectively).1  
The majority of venous thromboses in 
patients with OHSS occur in the upper 
limb, neck and head veins (60%).  This 
is the opposite of venous thromboses 
found in the non-pregnant population, 
where majority of venous thromboses 
are found in the lower extremities.  This 
could be due to estrogen-rich lymphatic 
drainage from ascitic fluid into the 
thoracic duct.6  There is approximately a 
4-12% associated risk in these patients 
of developing pulmonary embolism.  As 
opposed to venous events which can 
occur up to several weeks after OHSS 
onset, arterial thromboses are less 
common and occur concurrently with the 
onset of OHSS.  Arterial thromboses are 
predominately manifested by 
cerebrovascular accidents.6 
 
The diagnosis of mild OHSS is typically 
made by a history of ovarian stimulation, 
followed by typical symptoms of 
abdominal distension, nausea and 
vomiting.7  OHSS is further 
characterized by enlargement of the 
ovaries, as seen in this case review, 
with an acute fluid shift.  This results in 
ascites, pleural effusion and generalized 
edema.1  In a review of 2,902 patients 
with OHSS, 209 were found to have 
severe OHSS.  Severe cases are 
defined as ovarian enlargement >10 cm, 
massive ascites, pleural effusion, 
oliguria, liver dysfunction or 
hemoconcentration >45%.2, 3, 4 Critical 
OHSS is classified by thromboembolism 
or acute respiratory distress syndrome 
on top of severe symptoms.7  Of those 
with severe OHSS, dyspnea was the 
most common finding in 92% of 
patients, with pulmonary embolus (PE) 
found in 2%.3  Women that appear to be 
at the greatest risk for OHSS with 
thromboembolic complications are those 
with a personal or family history of 
thromboembolic disease, and those in 
whom pregnancy is achieved.8  
Compared with patients who develop 
arterial thrombosis following ART, those 
who develop venous thromboembolism 
are more likely to be pregnant.  The 
increased endogenous hCG associated 
with a pregnant state increases the 
hypercoagulability of the patient that is 
already initially hypercoagulable due to 
ovarian stimulation.6  
 
A high index of suspicion must be 
maintained to recognize 
thromboembolic events associated with 
OHSS.  If a woman conceives and is 
diagnosed with OHSS, prolonged 
monitoring should occur.  However, if 
she does not conceive, resolution of 
OHSS should occur by the time of her 
next withdrawal bleed.7  Outpatient 
management is appropriate for mild 
OHSS.  Patients should remain 
hydrated with no less than one liter of 
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fluid per day to keep urine output 
adequate (20-40 cc/hour) and to prevent 
hemoconcentration.  Hospitalization is 
necessary for severe OHSS if the 
patient has intractable abdominal pain, 
oliguria, ascites, dyspnea or electrolyte 
imbalance.2 
 
Pain control is the initial treatment when 
a patient is symptomatic with OHSS.  
This can be achieved with opiate 
medications when pain is severe.  
Nonsteroidal anti-inflammatory agents 
should be avoided because they can 
compromise renal function.  Nausea 
usually occurs secondary to ascites 
accumulation and therefore an effort 
should be made to reduce abdominal 
distention.  Paracentesis should be 
considered in severe distention or 
ascites with colloid replacement.  
Promethazine can be used safely in 
pregnant patients for nausea.7 
Studies indicate that empiric 
prophylactic unfractionated heparin or 
LMW heparin should be used in all 
patients found to have severe OHSS, 
regardless of evidence for or against 
thromboembolic disease.3  Routine 
screening and treatment for 
hypercoagulable state is not required at 
this time with ovulation induction or 
ART.  However, such monitoring may be 
cost-effective in patients with personal 
or family history of thromboses.  
Anticoagulation should always be 
started if thromboembolism is 
suspected.7  A review of 96 cases of 
thromboses related to OHSS stated that 
thromboprophylaxis should be 
considered for all patients with moderate 
to severe OHSS for 1-2 months beyond 
the clinical resolution.6 There is strong 
consensus that all women that are 
hospitalized with OHSS should also 
receive thromboprophylaxis while in the 
hospital.2  Furthermore, there is strong 
consensus that all OHSS patients with 
evidence of thromboembolic disease 
should be treated with full heparinization 
throughout their entire pregnancy, while 
other studies have suggested that 
patients be treated for a minimum of 6 
months.3  Evidence also states that no 
further investigation or treatment for 
pulmonary thromboembolic events is 
required postpartum in these patients 
beyond the 6 month total treatment 
period.3 
 
Conclusions  
 
From both this case report and relevant 
studies, it is in the best interest of 
patients undergoing ovulation induction 
and ovarian stimulation if physicians 
have a high index of suspicion for 
complications.  Ovarian hyperstimulation 
syndrome (OHSS) is iatrogenic and 
serious complications are preventable.  
In the case of thromboembolism related 
to OHSS in a pregnant patient, the 
patient should be fully heparinized for a 
minimum of 6 months, and often for the 
remainder of their pregnancy.  There is 
currently no indication to terminate a 
pregnancy that results in OHSS. 
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